Loading
A phase 1/2 trial of Mezigdomide, Bortezomib, Dexamethasone in multiple myeloma, run by Celgene, active and no longer recruiting.
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) is a phase 1/2 interventional study registered as NCT03989414 by Celgene, with 424 participants planned, started 2019-09-30 and due to reach its primary completion in 2026-11-30. Interventions recorded: CC-92480, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Daratumumab, Bortezomib.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Carfilzomib, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Bortezomib, Dexamethasone.
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Mezigdomide, Cereblon E3 ligase modulators (CELMoDs), Dexamethasone, PROTACs & molecular glues (targeted protein degradation).
Shares Cereblon E3 ligase modulators (CELMoDs), Daratumumab, Bortezomib, Dexamethasone.
Shares Mezigdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Elotuzumab, Carfilzomib, Bortezomib, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/